Vetoquinol

Vetoquinol

VETO.PA
Lure, France· Est.

Vetoquinol is an independent, family-founded animal health company with a mission to improve animal health and well-being through innovative pharmaceutical solutions. The company has built a strong international presence, generating over €500 million in annual revenue through a direct commercial footprint in key markets and a network of distributors. Its strategy focuses on therapeutic innovation, geographic expansion, and strategic acquisitions to strengthen its position in the high-growth animal health market, which is driven by trends in pet humanization, food safety, and livestock productivity.

VETO.PA · Stock Price

EUR 79.00-2.10 (-2.59%)
Market Cap: $1.1B

Historical price data

AI Company Overview

Vetoquinol is an independent, family-founded animal health company with a mission to improve animal health and well-being through innovative pharmaceutical solutions. The company has built a strong international presence, generating over €500 million in annual revenue through a direct commercial footprint in key markets and a network of distributors. Its strategy focuses on therapeutic innovation, geographic expansion, and strategic acquisitions to strengthen its position in the high-growth animal health market, which is driven by trends in pet humanization, food safety, and livestock productivity.

Companion Animal HealthLivestock HealthParasiticidesAnti-infectivesPain ManagementMetabolic Disorders

Technology Platform

Applied veterinary pharmaceutical R&D focused on novel formulations, delivery systems, and lifecycle management of pharmaceutical products for companion animals and livestock.

Funding History

1
IPOUndisclosed

Opportunities

Significant growth opportunities exist in the global rollout of flagship product Felpreva, geographic expansion into high-growth Asia-Pacific markets, and leveraging R&D in high-value chronic care segments like dermatology and pain management for companion animals.
The trend towards antibiotic reduction in livestock also creates demand for alternative health solutions.

Risk Factors

Key risks include regulatory hurdles for new product approvals, intense competition from larger animal health conglomerates, dependence on a limited number of key products for a significant portion of revenue, and potential supply chain disruptions affecting manufacturing and API sourcing.

Competitive Landscape

Vetoquinol competes against giants like Zoetis, Merck, and Boehringer Ingelheim. Its differentiation lies in its agility as an independent, mid-sized company, deep veterinary relationships, and focused innovation in specific therapeutic niches, allowing it to avoid direct, costly battles in the largest market segments.